(Total Views: 262)
Posted On: 10/19/2018 7:07:14 PM
Post# of 721
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Focused on Innovative Nicotine Delivery to Provide Healthier Alternatives to Lighting Up
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is on a quest in the development of healthier nicotine ingestion methods to provide consumers alternatives to lighting up. A recent article discussing the company’s novel drug delivery platform reads, “In a press release from August 2018, Lexaria announced a second-generation study in 40 rats. The study resulted in Lexaria’s formulation being four-times faster at reaching its peak level in brain tissue than the non-enhanced control formulation. In a press release (http://nnw.fm/6vu3X), Chris Bunka, chief executive officer of Lexaria, stated, ‘DehydraTECH delivery technology continues to demonstrate its superior effectiveness in delivering nicotine without the need for combustion or the need for inhalation whatsoever. Crossing the blood brain barrier is a significant achievement all on its own and this data confirms the outcome of our earlier first-generation test.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is on a quest in the development of healthier nicotine ingestion methods to provide consumers alternatives to lighting up. A recent article discussing the company’s novel drug delivery platform reads, “In a press release from August 2018, Lexaria announced a second-generation study in 40 rats. The study resulted in Lexaria’s formulation being four-times faster at reaching its peak level in brain tissue than the non-enhanced control formulation. In a press release (http://nnw.fm/6vu3X), Chris Bunka, chief executive officer of Lexaria, stated, ‘DehydraTECH delivery technology continues to demonstrate its superior effectiveness in delivering nicotine without the need for combustion or the need for inhalation whatsoever. Crossing the blood brain barrier is a significant achievement all on its own and this data confirms the outcome of our earlier first-generation test.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
